Weekly Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings on Jun 29, 2018

June 29, 2018 - By Ricky Cave

Cytokinetics, Incorporated (NASDAQ:CYTK) Corporate Logo
During Q1 2018 the big money sentiment decreased to 0.88. That’s change of 0.23, from 2017Q4’s 1.11. 19 investors sold all, 37 reduced holdings as Cytokinetics, Incorporated ratio is negative. 30 increased positions while 19 funds acquired positions. Funds hold 36.39 million shares thus 4.65% less from 2017Q4’s 38.16 million shares.
Alliancebernstein Limited Partnership invested in 43,100 shs. Grp Inc stated it has 26,556 shs. Swiss Comml Bank invested in 74,100 shs. Louisiana State Employees Retirement Sys stated it has 0.01% in Cytokinetics, Incorporated (NASDAQ:CYTK). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Howe Rusling Inc holds 0% or 148 shs. Goldman Sachs owns 354,263 shs. Weiss Multi, Alabama-based fund reported 35,000 shs. Essex Investment Limited Liability, a Massachusetts-based fund reported 84,690 shs. Zacks Investment Management, a Illinois-based fund reported 16,868 shs. Deutsche Natl Bank Ag invested in 0% or 111,457 shs. Sector Pension Investment Board holds 0% or 32,241 shs. 5.72 million are held by Bvf Il. Wellington Mngmt Grp Llp invested in 0% or 2.02 million shs. The Ohio-based Employees Retirement Sys Of Ohio has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK).

Cytokinetics, Incorporated registered $147,942 net activity with 0 insider purchases and 5 insider sales since January 16, 2018. On Tuesday, January 16 2,709 shs were sold by McDowell Caryn Gordon, worth $24,381. Malik Fady Ibraham had sold 3,000 shs worth $26,850.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

Total analysts of 2 have positions in Cytokinetics Inc (NASDAQ:CYTK) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 19, 2018 according to StockzIntelligence Inc Cytokinetics Inc has 4 analyst reports. On Friday, January 19 H.C. Wainwright maintained Cytokinetics, Incorporated (NASDAQ:CYTK) rating. H.C. Wainwright has “Buy” rating and $20.0 target. On Wednesday, February 21 Morgan Stanley maintained the shares of CYTK in report with “Overweight” rating. On Monday, June 18 the stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by H.C. Wainwright. On Friday, April 27 the firm has “Buy” rating given by H.C. Wainwright. Listed here are Cytokinetics, Incorporated (NASDAQ:CYTK) PTs and latest ratings.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0000 Maintain
21/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $17 New Target: $18 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain

CYTK hit $8.3 during the last trading session after $0.1 change.Cytokinetics, Incorporated has volume of 89,205 shares. Since June 29, 2017 CYTK has declined 37.37% and is downtrending. CYTK underperformed the S&P 500 by 49.94%.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The firm is valued at $449.84 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Currently it has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

For more Cytokinetics, Incorporated (NASDAQ:CYTK) news posted recently go to: Nasdaq.com, Benzinga.com, Nasdaq.com, Benzinga.com or Benzinga.com. The titles are as follows: “Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide” posted on June 18, 2018, “42 Stocks Moving In Monday’s Mid-Day Session” on June 18, 2018, “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to …” with a publish date: June 08, 2018, “60 Biggest Movers From Yesterday” and the last “Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share” with publication date: June 18, 2018.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: